As American Merck (MSD) accelerates its plan to launch the cancer drug Keytruda in a subcutaneous injection (SC) formulation instead of an intravenous injection (IV), a patent dispute has erupted over ...

Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...

The NHS is introducing a one-minute jab that could help tens of thousands of cancer patients.

Tens of thousands of patients could benefit from a one-minute jab being rolled out on the NHS for more than a dozen cancers.

Until now, patients have had to spend hours on a drip to get the drug pembrolizumab (Keytruda) to treat their cancer.